In a study conducted by Fenny et al., in mice, it was demonstrated that LYC decreases serum levels of TG and non-esterified fatty acids (NEFA) and attenuates liver steatosis with a decreased expression of lipogenic genes, such as acetyl-CoA carboxylase-1 (ACC1), fatty acid synthase (FAS) and sterol regulatory element-binding protein 1c (SREBP-1c) (Figure 2) [58]. Here, ACACA is linked to fatty liver disease.